Anzeige
Mehr »
Montag, 06.04.2026 - Börsentäglich über 12.000 News
Diese Entwicklung im KI-Sektor könnte unterschätzt werden - und sie betrifft die Energieversorgung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CT5N | ISIN: SE0015988274 | Ticker-Symbol: 5KC
Frankfurt
02.04.26 | 15:25
0,171 Euro
-1,72 % -0,003
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PILA PHARMA AB Chart 1 Jahr
5-Tage-Chart
PILA PHARMA AB 5-Tage-Chart

Aktueller Chart PILA PHARMA Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
PILA PHARMA AB-Investoren interessieren sich auch für diese Wertpapiere
Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights- Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications - - Interim Ph2...
► Artikel lesen
Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory OfficerCARLSBAD, Calif., Dec. 1, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation...
► Artikel lesen
Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights- Dosed first patients with dabogratinib in BEACH301 and SURF302; interim results from both studies expected in 2026 - - Expanded development of dabogratinib...
► Artikel lesen
Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial ResultsEncouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics...
► Artikel lesen
Erasca, Inc.: Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and VopimetostatERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO...
► Artikel lesen
Erasca, Inc.: Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca's diversified IP portfolio for RAS-driven cancers Initial Phase...
► Artikel lesen
Morning Market Movers: Taoping, Janux Therapeutics, MongoDB, American Bitcoin Corp. See Big SwingsCANBERA (dpa-AFX) - At 7:25 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening...
► Artikel lesen